On March 31, 2023,
B. Riley Securities
initiated coverage of Silk Road Medical with
a Buy recommendation.
Analyst Price Forecast Suggests 46.50% Upside
As of March 30, 2023,
the average one-year price target for Silk Road Medical is $57.32.
The forecasts range from a low of $46.46 to a high of $66.15.
The average price target represents an increase of 46.50% from its latest reported closing price of $39.13.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Silk Road Medical
is $175MM, an increase of 26.08%.
The projected annual non-GAAP EPS
is -$1.49.
What are Large Shareholders Doing?
Wasatch Advisors
holds 3,063K shares
representing 7.96% ownership of the company.
In it’s prior filing, the firm reported owning 3,497K shares, representing
a decrease
of 14.16%.
The firm
decreased
its portfolio allocation in SILK by 0.34% over the last quarter.
SMCWX – SMALLCAP WORLD FUND INC
holds 2,967K shares
representing 7.71% ownership of the company.
In it’s prior filing, the firm reported owning 2,792K shares, representing
an increase
of 5.90%.
The firm
increased
its portfolio allocation in SILK by 16.65% over the last quarter.
Capital World Investors
holds 2,967K shares
representing 7.71% ownership of the company.
In it’s prior filing, the firm reported owning 2,792K shares, representing
an increase
of 5.90%.
The firm
increased
its portfolio allocation in SILK by 18.51% over the last quarter.
Alliancebernstein
holds 2,617K shares
representing 6.80% ownership of the company.
In it’s prior filing, the firm reported owning 3,339K shares, representing
a decrease
of 27.58%.
The firm
decreased
its portfolio allocation in SILK by 26.87% over the last quarter.
Clearbridge Investments
holds 1,673K shares
representing 4.35% ownership of the company.
In it’s prior filing, the firm reported owning 1,543K shares, representing
an increase
of 7.72%.
The firm
increased
its portfolio allocation in SILK by 24.66% over the last quarter.
What is the Fund Sentiment?
There are 436 funds or institutions reporting positions in Silk Road Medical.
This is an increase
of
77
owner(s) or 21.45% in the last quarter.
Average portfolio weight of all funds dedicated to SILK is 0.26%,
an increase
of 1.60%.
Total shares owned by institutions increased
in the last three months by 8.52% to 52,716K shares.
The put/call ratio of SILK is 0.23, indicating a
bullish
outlook.
Silk Road Medical Background Information
(This description is provided by the company.)
Silk Road Medical, Inc.,is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
